list of glp-1 drugs for weight loss Unlocking The Power GLP-1 Weight-Loss Drugs Could Address
Description
This is progressive loss of medication effectiveness despite maintained dosing
The most common drug-related adverse events were nausea, constipation and vomiting
The participants in the studies were 43,522 with DPP-4 inhibitors, 60,080 with GLP-1RA, and 77,541 with SGLT-2 inhibitors, for a total number of 181,143 participants
GLP-1 has been proven to be a useful adjuvant therapy in type-2 diabetes mellitus, metabolic syndrome, and hyperglycemia
Novo Nordisk maintains first-to-market advantage with semaglutide across diabetes (Ozempic), obesity (Wegovy), and oral (Rybelsus) formulations, with the oral version launching in January 2026 following December 2025 FDA approval [3]
